chloroquine has been researched along with crizotinib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belani, CP; Cheng, Y; Ji, C; Ji, S; Patel, R; Ren, X; Wang, M; Wu, H; Yang, JM; Zhang, L; Zhang, Y | 1 |
| AlSaati, T; Beau, I; Brousset, P; Codogno, P; Desquesnes, A; Espinos, E; Frentzel, J; Giuriato, S; Lamant, L; Le Gonidec, S; Meggetto, F; Mitou, G | 1 |
2 other study(ies) available for chloroquine and crizotinib
| Article | Year |
|---|---|
Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer.
Topics: Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Chloroquine; Crizotinib; Down-Regulation; Drug Resistance, Neoplasm; Female; Heterografts; Humans; Lung Neoplasms; Mice, Nude; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; TOR Serine-Threonine Kinases | 2014 |
Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma.
Topics: Anaplastic Lymphoma Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line, Tumor; Cell Survival; Chloroquine; Crizotinib; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Lymphoma, Large-Cell, Anaplastic; Mice, Inbred NOD; Mice, SCID; Microtubule-Associated Proteins; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; RNA Interference; Signal Transduction; Time Factors; Transfection; Xenograft Model Antitumor Assays | 2015 |